Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | CPS1 | P31327 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045533 | 0.85 | CYP3A4 (0.45) | KMT2ASIGMAR1 | |
| SCHEMBL6045603 | 0.76 | LMNA (0.44) | GAARAB9AKMT2ASIGMAR1MAPT | |
| SCHEMBL6045634 | 0.74 | CPS1 (0.35) | BACE1KMT2ASIGMAR1CPS1 | |
| SCHEMBL6045710 | 0.73 | SMN1; SMN2 (0.44) | KMT2A | |
| SCHEMBL11565288 | 0.72 | NPFFR1 (0.44) | BACE1SIGMAR1TMEM97MAPT | |
| SCHEMBL6045431 | 0.71 | PDK1 (0.34) | BACE1CPS1 | |
| Fumaric Acid SCHEMBL6045619 | 0.71 | SIGMAR1 (0.34) | BACE1GAAKMT2ASIGMAR1CPS1 | |
| Fumaric Acid SCHEMBL6045613 | 0.71 | SIGMAR1 (0.34) | BACE1GAAKMT2ASIGMAR1CPS1 | |
| SCHEMBL6045741 | 0.71 | SMN1; SMN2 (0.55) | BACE1SIGMAR1TMEM97MAPT | |
| SCHEMBL28791743 | 0.71 | HRH2 (0.41) | BACE1SIGMAR1TMEM97MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | BACE1 3158/4885GAA 4863/4885RAB9A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.